Anti Inflammatory News and Research

RSS

Study: Ultrasound treatments may prevent acute kidney injury

Ultrasound treatments may prevent acute kidney injury that commonly arises after major surgery, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings suggest that this simple and noninvasive therapy may be an effective precaution for patients at risk.

2 Aug 2013

Omeros submits OMS302 NDA to FDA for patients undergoing ILR surgery

Omeros Corporation announced that the company recently submitted a New Drug Application to the U.S. Food and Drug Administration for approval of OMS302 for use in patients undergoing intraocular lens replacement surgery.

1 Aug 2013

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.

31 Jul 2013

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia.

30 Jul 2013

FDA accepts NDA for MNK-795 oral formulation

Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.

30 Jul 2013

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals announced today that on July 26, 2013 it submitted its New Drug Application to the U.S. Food and Drug Administration for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

30 Jul 2013

Symptoms, first-aid treatments and prevention tips for insect bites

Whether they are invading your picnic, hitching a ride on your skin or just buzzing around your head, bugs are an annoying and unavoidable part of summer. Still, there are times when bugs are just a nuisance and times when they can cause serious illness or injury.

24 Jul 2013

Discovery may help explain how anti-inflammatory steroid drugs work

A gene long presumed dead comes to life under the full moon of inflammation, Stanford University School of Medicine scientists have found.

23 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

Researchers discover new functions for PTPN22 gene linked with autoimmune disease

Researchers at the University of Minnesota have identified infection-fighting and inflammation-suppressing functions for a gene associated with human autoimmune disease.

20 Jul 2013

New data identifies specific cellular pathways by which RNS60 impacts Alzheimer's Disease

On Wednesday Revalesio Corporation presented new data at the Alzheimer's Association International Conference that identifies the specific cellular pathways by which Revalesio's lead investigational product, RNS60, impacts Alzheimer's Disease. This research, conducted in partnership with Rush University Medical Center, investigates a new category of therapeutics using Revalesio's novel nanotechnology platform.

19 Jul 2013

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its abstract "Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule for the Topical Treatment of Toenail Onychomycosis" was accepted for oral presentation at the 2013 APMA Annual Scientific Meeting (The National) to be held in Las Vegas, Nevada.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Virginia Commonwealth University receives $1.8M grant to study biology of allergic disease

The National Institutes of Health has awarded Virginia Commonwealth University a grant totaling $1.8 million to study the biology of allergic disease - work which may one day point researchers to the development of therapies to fight asthma, allergy and inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and heart disease.

18 Jul 2013

Magnets could be used for directing stem cells, may help treat heart and vascular diseases

Magnets could be a tool for directing stem cells' healing powers to treat conditions such as heart disease or vascular disease.

17 Jul 2013

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.

16 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.

11 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Anti Inflammatory News and Research

Study: Ultrasound treatments may prevent acute kidney injury

Omeros submits OMS302 NDA to FDA for patients undergoing ILR surgery

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

FDA accepts NDA for MNK-795 oral formulation

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Symptoms, first-aid treatments and prevention tips for insect bites

Discovery may help explain how anti-inflammatory steroid drugs work

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Researchers discover new functions for PTPN22 gene linked with autoimmune disease

New data identifies specific cellular pathways by which RNS60 impacts Alzheimer's Disease

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Virginia Commonwealth University receives $1.8M grant to study biology of allergic disease

Magnets could be used for directing stem cells, may help treat heart and vascular diseases

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Soligenix announces personalized medicine collaboration with SciClone

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News